We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

50 hedge funds and large institutions have $34.8M invested in Enzo Biochem, Inc. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

8% more capital invested

Capital invested by funds: $32.2M → $34.8M (+$2.62M)

4% less funds holding

Funds holding: 5250 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

97% less call options, than puts

Call options by funds: $6K | Put options by funds: $188K

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
1.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
15
Reduced
13
Closed
6
Calls
$6K
Puts
$188K
Net Calls
-$182K
Net Calls Change
-$96K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$6.62M -$2.68M -1,079,376 -32%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$5.75M -$2.31K -931 -0%
Millennium Management
3
Millennium Management
New York
$3.54M -$779K -314,250 -21%
ClearBridge Investments
4
ClearBridge Investments
New York
$3.42M -$86.8K -34,978 -3%
BIT
5
BlackRock Institutional Trust
California
$2.58M +$239K +96,562 +12%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.48M +$73K +29,453 +4%
CCM
7
Corsair Capital Management
New York
$1.89M +$58.8K +23,723 +4%
PRC
8
Platte River Capital
Colorado
$1.55M +$1.32M +531,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$1.01M +$153K +61,737 +22%
BCM
10
Bridgeway Capital Management
Texas
$701K
CCT
11
Chemung Canal Trust
New York
$636K -$98.6K -39,745 -15%
AA
12
Ancora Advisors
Ohio
$438K +$33.7K +13,592 +10%
Goldman Sachs
13
Goldman Sachs
New York
$433K -$50.2K -20,254 -12%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$334K -$221 -89 -0.1%
Two Sigma Investments
15
Two Sigma Investments
New York
$317K +$206K +83,028 +323%
Morgan Stanley
16
Morgan Stanley
New York
$313K -$19.5K -7,875 -7%
CFB
17
Cullen/Frost Bankers
Texas
$300K
BFA
18
BlackRock Fund Advisors
California
$296K +$10.5K +4,230 +4%
Northern Trust
19
Northern Trust
Illinois
$281K -$7.64K -3,081 -3%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$252K
AAP
21
Ardsley Advisory Partners
Connecticut
$248K +$211K +85,000 New
Charles Schwab
22
Charles Schwab
California
$216K
KCM
23
Kempner Capital Management
Texas
$204K
GCP
24
GSA Capital Partners
United Kingdom
$185K -$12.6K -5,100 -7%
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$165K

ENZ Hedge Fund Activity: Q4 2013 in Review

50 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2013, worth a combined $34.8M — up 8.1% from $32.2M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ENZ and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was Platte River Capital, opening a new position worth an estimated $1.32M. The largest seller was RA Capital Management, cutting an estimated $2.68M.

  • 50 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2013, down from 52 in Q3 2013.
  • Funds reported $34.8M of Enzo Biochem, Inc. stock for Q4 2013, up 8.1% quarter-over-quarter.
  • 4 funds opened new Enzo Biochem, Inc. positions in Q4 2013 and 6 closed out, a net change of -2 holders.
  • The largest Enzo Biochem, Inc. buyer in Q4 2013 was Platte River Capital, an estimated $1.32M added.
  • The largest Enzo Biochem, Inc. seller in Q4 2013 was RA Capital Management, an estimated $2.68M sold.

Based on aggregated 13F filings for Q4 2013.